

Technology Transfer

Ideas to Impact



*The purpose of our Technology Transfer unit is to partner with the Rutgers community to **encourage** deliberate innovation, **protect and leverage** Rutgers intellectual property, **foster** collaboration with industry, and **enable** entrepreneurship.*

For Licensing/Collaborations Opportunities:
marketingbd@research.rutgers.edu

<https://research.rutgers.edu/researcher-support/innovate>

<https://techfinder.rutgers.edu/>

A treatment to promote skin wound healing

Inventor: William Gause & Rick Maizels
NJMS, Rutgers Health
& School of Infection-Immunity, Univ of Glasgow

Rutgers docket number/s: S11-119


For Licensing/Collaborations Opportunities:

marketingbd@research.rutgers.edu


innovate@research.rutgers.edu

DO NOT CIRCULATE WITHOUT PRIOR PERMISSION


Cells in the helminth-induced type 2 response play a role in the tissue repair response.





Migrating Nb larvae induces lung injury and airway neutrophilia, which are quickly resolved starting 4 days after inoculation



IL-4 or IL-13-mediated signaling controls acute hemorrhaging and inflammation after *N. brasiliensis* lung migration at day 4





ES products including synthesized small molecule analogues are now being tested in experimental models and clinical trials



Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings.

HES accelerates wound closure in a 2-D *in vitro* scratch test.




0.08 μ g/ml

0.8 μ g/ml

1 μ g/ml

Medium


ES products include proteins and associated moieties




J. Med. Chem. 2013, 56, 9982–10002

TGF-β Mimic (TGM)


e



- A member of the CCP (Complement Control Protein) superfamily
- Structurally distinct from TGF-β
- Shares no sequence homology with TGF-β
- Twice the size (404aa) of TGF-β homodimer
- Is constitutively active compared to TGF-β which has to be processed




in vivo wound biopsy study design







Tegaderm






TGM + 1.5% Carboxymethylcellulose/PBS





TGM significantly enhances the rate of wound closure with increases in serous volume and concentrations of factors associated with augmented wound healing.



Enhanced tissue thickness suggests that TGM is amplifying the formation and increasing the strength of the developing tissue as it heals and matures.



With TGM treatment, there was a significant increase in wound leading-edge thickness by day 4, which correlates with the enhanced wound closure that was first observed at this early time point.










On day 12, TGM-treated wounds showed enhanced skin tissue regeneration with reduced scarring.

Enhanced basketweave collagen morphology and formation of hair follicles with complete sebaceous glands were observed

Day 12

Day 12




Naive Day 7 Day 12


PBS vehicle

TGM


TGM mediates enhanced wound healing through TGF- β R domain activity.



Modified from Smyth *et al*, Int J Parasitol , 2018, 48(5):379-385



Day 7





Summary

- Daily TGM application significantly enhances the rate of cutaneous wound closure at 5 days following injury.
- TGM demonstrated overall better wound reorganization at later phases as observed through collagen orientation and hair follicles.
- TGM's activity leads to increased inflammation into the wound bed including accumulation of migratory Ly6C+ myeloid cells.
- TGM treatment reprograms macrophages favoring expansion of a CD206-subset expressing markers associated with wound healing.
- TGM's wound healing activity and macrophage modulation is predominantly mediated through TGF- β R signaling.

https://techfinder.rutgers.edu/tech/A_treatment_to_promote_skin_wound_healing

TGM demonstrates greater therapeutic potential compared to TGF- β

- Is constitutively active compared to TGF- β which had to be processed
- Binds independently to both T β RI and T β RII
 - TGM binds directly to T β RI with high affinity
- TGM proved to be more active at a lower dose
- Easier to produce
- Low immunogenicity
- Very stable during storage



Acknowledgments

Dr. William Gause Laboratory

Katherine Lothstein

Fei Chen

Wenhui Wu

Ariel Millman

Pankaj Mishra

Mark Palma

Darine El-Naccache

Dr. Joseph Urban

USDA

Dr. Yosuke Kumamoto Laboratory

Dr. Naoya Tatsumi

Jihad El-Fenej

Alejandro Davila-Pagan

Dr. Amariliz Rivera Laboratory

Keyi Wang

Dr. Jason Weinstein Laboratory

Gina Sanchez

Dr. Alexander Lemenze

NJMS Flow Cytometry and Immunology Core Laboratory

Dr. Sukhwinder Singh

Tammy Galenkamp

Cellular Imaging and Histology Core

Luke Fritzky

Joel Pierre

The Center for Advanced Proteomics Research

Dr. Hong Li

Dr. Tong Liu

Comparative Medicine Resources (CMR)

Marleata Anderson

Dr. Rick Maizels Laboratory

Dr. Danielle Smyth

Claire Ciancia

Marta Campillo Poveda